Compare KURA & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KURA | CBLL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 260 | 280 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 841.6M | 750.1M |
| IPO Year | 2015 | N/A |
| Metric | KURA | CBLL |
|---|---|---|
| Price | $9.23 | $16.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $25.56 | $23.20 |
| AVG Volume (30 Days) | ★ 1.2M | 285.3K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,482,000.00 | N/A |
| Revenue This Year | $28.28 | $29.57 |
| Revenue Next Year | $106.37 | $28.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $5.45 | $10.85 |
| 52 Week High | $12.49 | $24.33 |
| Indicator | KURA | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 31.17 |
| Support Level | $8.95 | $11.17 |
| Resistance Level | $9.82 | $20.25 |
| Average True Range (ATR) | 0.43 | 1.10 |
| MACD | 0.01 | -0.52 |
| Stochastic Oscillator | 50.34 | 9.80 |
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.